Prostate-specific antigen glycoprofiling as diagnostic and prognostic biomarker of prostate cancer. Issue 2 (15th February 2019)

• Record Type: Journal Article
• Authors: Tkac, Jan; Gajdosova, Veronika; Hroncekova, Stefania; Bertok, Tomas; Hires, Michal; Jane, Eduard; Lorencova, Lenka; Kasak, Peter
• Is Part Of: Interface focus. Volume 9:Issue 2(2019)
• Publication Date: 2019-02-15
• Subjects: prostate cancer -- diagnostics -- biomarkers -- lectins -- glycans -- prostate-specific antigen; Physical sciences -- Periodicals; Life sciences -- Periodicals; 500
• DOI: 10.1098/rsfs.2018.0077
• Languages: English
• ISSNs: 2042-8898

Abstract

Abstract : The initial part of this review details the controversy behind the use of a serological level of prostate-specific antigen (PSA) for the diagnostics of prostate cancer (PCa). Novel biomarkers are in demand for PCa diagnostics, outperforming traditional PSA tests. The review provides a detailed and comprehensive summary that PSA glycoprofiling can effectively solve this problem, thereby considerably reducing the number of unnecessary biopsies. In addition, PSA glycoprofiling can serve as a prognostic PCa biomarker to identify PCa patients with an aggressive form of PCa, avoiding unnecessary further treatments which are significantly life altering (incontinence or impotence).